EVE Health Group Limited (AU:EVE) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
EVE Health Group reports a 17% increase in Meluka Australia’s revenue for the September quarter, driven by the re-launch of its probiotic powder supplement and the introduction of the Gut Starter range. The company also completed the sale of its Robyndale tea tree property, strengthening its financial position and enabling exploration of strategic acquisitions. EVE Health Group continues to focus on expanding its market presence with ongoing product innovation and potential acquisitions.
For further insights into AU:EVE stock, check out TipRanks’ Stock Analysis page.